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Abstract
Elucidation of the neural substrates underlying complex animal behaviors depends on precise 
activity control tools, as well as compatible readout methods. Recent developments in 
optogenetics have addressed this need, opening up new possibilities for systems neuroscience. 
Interrogation of even deep neural circuits can be conducted by directly probing the necessity and 
sufficiency of defined circuit elements with millisecond-scale, cell type-specific optical 
perturbations, coupled with suitable readouts such as electrophysiology, optical circuit dynamics 
measures and freely moving behavior in mammals. Here we collect in detail our strategies for 
delivering microbial opsin genes to deep mammalian brain structures in vivo, along with protocols 
for integrating the resulting optical control with compatible readouts (electrophysiological, optical 
and behavioral). The procedures described here, from initial virus preparation to systems-level 
functional readout, can be completed within 4–5 weeks. Together, these methods may help in 
providing circuit-level insight into the dynamics underlying complex mammalian behaviors in 
health and disease.
INTRODUCTION
Understanding the circuit-level functional organization of the brain will have important 
implications for both basic and clinical neuroscience. In particular, we have found that 
optical manipulation of activity in neural circuits with light-sensitive rhodopsins, such as the 
Chlamydomonas channelrhodopsin-2 (ChR2)1,2, Volvox channel-rhodopsin-1 (VChR1)3, 
Natronomonas halorhodopsin (NpHR)4 (Fig. 1a) and synthetic rhodopsin/GPCR chimeras5 
(optoXRs; Fig. 1b), may help in illuminating both the normal circuit function and major 
disease mechanisms6–19. Here we illustrate the critical steps we have developed for the 
implementation of this optogenetic6,7 approach to probe the function of deep brain circuit 
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elements in mammals. We first review the basic optogenetic control tools we have 
described, followed by discussion of optimization of expression, targeting and readout 
technology. We then present the necessary materials and outline a detailed series of our 
experimental protocols for integrating optogenetic neuronal manipulation with in vivo and ex 
vivo readout methods, including electrophysiological and optical measures.
Experimental design considerations
Temporally precise genetically encoded control—Classical neuronal manipulation 
techniques (electrical, pharmacological and genetic) either simultaneously affect 
surrounding cells and processes in addition to the target population or have slow kinetics 
and poor reversibility, thereby severely limiting the strength of conclusions that can be 
drawn. To overcome these spatial and temporal limitations, microbial and chimeric-
vertebrate opsin genes (Table 1) have been developed recently to control highly-defined 
electrical (Fig. 1a) and biochemical (Fig. 1b) activity with cell-type selectivity, high 
temporal precision and rapid reversibility. As most neurons in the brain are not naturally 
light-sensitive, selective expression of opsin genes in targeted neural populations makes it 
possible to specifically control the activity in these populations, and the resulting fast on–off 
kinetics make it possible to evoke or inhibit neural activity within milliseconds, on a 
timescale relevant to the physiological brain functions.
At present, light-activated cation channels from two distinct algal species, 
channelrhodopsin-2 from Chlamydomonas reinhardtii (ChR2)1,2,20 and channelrhodopsin-1 
from Volvox carteri (VChR1)3 (Fig. 1a, left and middle), have proven to be a powerful pair 
of tools for controlling neural activity. ChR2 is maximally activated by blue light at 470 nm, 
whereas VChR1 remains significantly light sensitive even at 589 nm, a wavelength at which 
(importantly) ChR2 is no longer responsive (Fig. 1c). Both ChR2 (deactivation time 
constant ~12 ms) and VChR1 (deactivation time constant ~120 ms) are able to transduce 
trains of millisecond-duration light flashes into defined spike trains up to 30–50 Hz1,2,8. 
Conversely, the chloride-pumping halorhodopsin from Natronomonas pharaonis (NpHR) 
has been shown to hyperpolarize neurons upon illumination with yellow light (Fig. 1c). 
Because of sufficient spectral separation, NpHR and ChR2 can simultaneously be expressed 
in the same neurons to enable bidirectional optical control of neural activity. Moreover, both 
use all-trans retinal as the chromophore, which is abundantly present in mammalian brain 
tissue, and therefore these optogenetic tools are fully functional without the addition of 
chemical cofactors in vivo4.
Optimizing expression and function—For all of these proteins, expression issues will 
determine crucial aspects of performance. For example, because of the inactivation kinetics 
of ChR2, higher-expressing cells will be able to follow fast spike frequencies for longer 
periods of time, as these cells will be able to employ larger pools of the remaining non-
inactivated ChR2. As another example, without the proper targeting sequences, high levels 
of microbial protein expression in mammalian cells can result in the aggregation of 
misfolded proteins in the Golgi, the endoplasmic reticulum and other intracellular 
compartments. As the conductance of individual rhodopsins is relatively low (picosiemens 
or less for ChR2, and even lower for NpHR as a pump, due to its 1:1 coupling between 
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photon absorption and ion flux), it is critical to maximize the number of molecules that are 
properly integrated into the cytoplasmic membrane, in addition to optimizing transcription 
of the opsin genes. For this reason, we have been constructing enhanced versions of 
halorhodopsin (eNpHR) by optimizing membrane trafficking sequences to increase the 
efficiency of membrane targeting21,22. eNpHR exhibits higher levels of membrane 
expression and more robust photocurrents, and similar modifications could be applied to 
optimize other microbial light-activated proteins for enhanced photocurrents.
Molecular engineering is also leading to expanded and refined function of these microbial 
proteins by altering spectral properties, conductance or kinetics. One point mutation (H134R 
in ChR2 (ref. 23)) has been shown to result in 2–3× enhanced cellular photocurrents24 (but 
at the expense of slowed deactivation). Channelrhodopsin deactivation can be slowed so 
much that a novel utility is achieved; several C128 point mutants of ChR2 exhibit profound 
bistability, converting a brief pulse of light into a stable step in membrane potential25. 
Transduced cells are (at steady state) responsive to light at >100× lower light levels because 
of delayed exit of these proteins from the open state25. These C128 mutants are still 
activated by blue (470 nm) light, but photocurrents elicited by the opening of ChR2(C128A) 
and ChR2(C128S) can effectively be terminated by a pulse of green (542 nm) light. These 
engineered step function opsins (SFO) can optically sensitize cells to native patterns of 
input, by providing a sustained step depolarization of the target cell membrane potential that 
can increase excitability. In many settings this approach will be preferable to simply driving 
user-defined trains with possibly inappropriate spike times. Related experimental leverage in 
terms of more natural control of native spike timing may also result from use of the optoXRs 
(Fig. 1; Table 1), which achieve temporally precise modulation of intra-cellular biochemical 
activity rather than direct control of spiking; of course, in some settings direct control of 
spike timing is the desired effect, in which case ChR2 or VChR1 are employed.
Genetic strategies for targeting expression to specific neural populations—
Opsin genes can be selectively expressed in defined subsets of neurons in the brain using a 
variety of expression targeting strategies26–28. Here we focus on those techniques that have 
been shown to be effective in achieving functional expression of optogenic proteins in vivo.
Viral expression systems: unlike many other genetic targeting strategies requiring the use of 
transgenic animal models, viral vectors29 based on lentivirus and adeno-associated virus 
(AAV) can be used to target opsin gene expression in a wide range of experimental subjects 
ranging from rodents to primates. Specifically, high titer lentivirus and AAV-based vectors 
(>109 transducing units (TU) ml−1 for lentivirus and >1012 genome copies (gc) ml−1 for 
AAV vectors) can be easily produced in Biosafety Level 2-certified tissue-culture facilities 
in 1–2 weeks, or alternatively obtained through a number of virus production facilities (e.g., 
Viral Vector Core, University of North Carolina, Chapel Hill, North Carolina, USA, and 
Virapur, LLC., San Diego, California, USA). These transduction methods have been shown 
to achieve high levels of functional opsin gene expression in neurons for several months.
Although most common AAV (Fig. 1d, top) and lentivirus (Fig. 1d, middle) vectors carry 
strong ubiquitous or pan-neuronal promoters, some more specific promoter fragments retain 
cell type-specificity, allowing selective targeting in animals where transgenic technology is 
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not accessible. In addition, viruses are capable of mediating high levels of opsin gene 
expression by introducing multiple gene copies into each target cell, an important function 
for overcoming the low transcriptional activity of some cell-specific promoters. In general 
for rodent brains, opsin gene expression reaches functional levels within 3 weeks after AAV 
injection and within 2 weeks after lentivirus injection. We have found that to reach the high 
steady-state levels of expression in distal axonal processes, longer periods of expression (>6 
weeks) may be necessary.
Electroporation: specific cell types can also be targeted developmentally with in utero 
electroporation24,30, e.g. at precisely timed embryonic days in mouse to target cortical layers 
II and III (E15.5), layer IV (E13.5) or layers V and VI (E12.5). In utero electroporation also 
can be used to express opsin genes in the inhibitory neurons of the striatum or in the 
hippocampus30,31. In addition, unlike viral delivery methods, in utero electroporation can be 
used to deliver DNA of any size, therefore permitting the use of larger promoter segments to 
achieve higher cell-type specificity (Table 2). Electroporation also allows high copy number 
of genes to be introduced into the target cells.
Transgenic mice: transgenic technologies can be used to restrict gene expression to specific 
subsets of neurons in mice or rats. Using either short transgene cassettes carrying 
recombinant promoters or bacterial artificial chromosomes (BACs)-based transgenic 
constructs, microbial opsin genes can be functionally expressed in subsets of neurons in 
intact circuits. Several transgenic mouse lines carrying ChR2 under the Thy-1 promoter, that 
have proven useful for a wide array of experiments, have been generated without any 
noticeable behavioral or reproductive defects22,32,33.
Conditional expression systems: although cell-specific promoters are effective at restricting 
gene expression to subsets of genetically defined neurons, some promoters have weak 
transcriptional activity. Therefore when used to direct the expression of microbial opsin 
genes, many cell-specific promoters are unable to achieve the level of opsin gene expression 
necessary to mediate effective action potential firing or blockade. To amplify the 
transcriptional activity in a cell-specific manner, conditional AAV vectors34–36 (Fig. 1d, 
bottom) have been developed recently to capitalize on the numerous cell-specific Cre-driver 
transgenic mouse lines that have been made available by individual labs and collective 
projects such as GENSAT. These conditional AAV expression vectors carry transgene 
cassettes that are activated only in the presence of Cre, and the use of strong ubiquitous 
promoters to drive the Cre-activated transgene selectively amplifies opsin gene expression 
level only in the cells of interest.
Circuit-specific cell targeting based on neuronal projection patterns: neurons identified by a 
given genetic marker can still be quite diverse, either receiving innervations from or sending 
axonal projections to distinct brain regions. For example, some of the tyrosine hydroxylase-
expressing dopaminergic (DA) neurons in the midbrain innervate reward-related brain 
structures such as the nucleus accumbens, whereas other DA neurons project to motor 
control centers such as the striatum, and spatial separation between different DA neuron 
populations is not complete. However, as rhodopsins are trafficked to cellular processes 
including axons, the axonal processes may become light sensitive. Therefore, it may be 
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possible to selectively control a connection-defined neural pathway through focal injection 
of viral vectors followed by photostimulation of axon terminals in the target downstream 
brain structure. For example, to study the medial prefrontal cortical afferents in the 
amygdala, it is possible to inject a viral vector carrying ChR2–enhanced yellow fluorescent 
protein (EYFP) into the medial prefron-tal cortex and implant the stimulation optical fiber 
into the amygdala. It is even possible to combinatorially interrogate the role of multiple 
subsets of afferent fiber bundles using multiple optogenetic proteins with distinct spectral 
sensitivities (e.g., using yellow light to activate VChR1-expressing afferents independent of 
ChR2-expressing afferents within the same neural tissue).
A number of plant and microbial proteins and several viral vectors with unique anterograde- 
or retrograde-transporting properties28,37,38 may be engineered with recombinases to 
activate gene expression in sub-populations of neurons with cell type- and circuit specificity. 
For example, expression of fusion proteins containing Cre and either wheat germ agglutinin 
or tetanus toxin fragment C in the cell bodies of one brain region will allow the recombinase 
to be trans-neuronally delivered to up- or down-stream neurons in another brain region. 
Similarly, viral vectors39,40, such as rabies virus28 or herpes simplex virus 1 (HSV-1) 
vectors, can be used for retrograde gene delivery, and the H129 strain76 of HSV might be 
developed for anterograde gene delivery. When combined with conditional expression 
systems, either Cre-dependent transgenic mice or viral vectors, this strategy may allow 
circuit-specific gene expression in a variety of mammalian animal models not limited to 
mice. Moreover, microbial protein expression can also be restricted to specific intra-cellular 
compartments and locations by fusing to targeting motifs and protein domains24,41.
Readouts compatible with optogenetic control of intact circuits—Several classes 
of circuit readout can be made compatible with optogenetic control. First, voltage-sensitive 
dye (VSD) imaging is an effective approach for monitoring the electrical activity of large 
populations of neurons ex vivo and in vivo with high temporal resolution. VSDs are 
lipophilic molecules whose optical absorbance or emission properties vary depending on the 
electrical potential across the membrane42. Along with high-speed cameras to capture 
changes in the optical signal, VSD imaging allows researchers to measure electrical activity 
changes in neurons on the millisecond timescale and with micro-scale spatial 
resolution43–46. Previously, we have utilized VSDs to image ex vivo and quantify the 
activity of neural circuits involved in depression-related behaviors47. VSD imaging can also 
be combined with optogenetic techniques to conduct all-optical stimulation and imaging of 
evoked circuit responses in brain slices. Optically compatible VSDs such as RH-155 
(absorption ~700 nm) are sufficiently separated from the excitation peaks of ChR2, VChR1 
and NpHR48 (Fig. 1c) to permit multimodal all-optical stimulation and imaging. The 
protocol described below for fast all-optical interrogation has been optimized for brain slices 
from Thy1::ChR2–YFP transgenic mice32,33.
A second class of readout involves in vivo control integrated with either or both of electrical 
recording and behavioral measures. Targeting light-stimulation and electrical-recording 
devices to reach the site of opsin gene delivery poses an experimental challenge that can 
readily be overcome with the appropriate protocol. We have developed a fiber optic-based 
optical neural interface (ONI) that meets this challenge49. The ONI uses stereotactically 
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implanted (Fig. 2a–i) cannula guides for targeted virus infusion and light delivery into 
desired brain structures (Fig. 3a).
Stereotactic targeting of brain structures: stereotactic surgeries can be used to target opsin 
gene expression to genetically defined and spatially restricted neuronal populations in the 
brain and can also be used to place a light delivery device to target the transduced cells using 
widely available brain atlas coordinates50 as described below. There are two major methods 
for stereotactically delivering lentiviral or AAV vectors to the brain. In the first approach, 
primarily applicable for in vitro acute slice electrophysiology or imaging studies, the viral 
vectors can be injected through a glass needle, targeted to the brain region of interest via a 
stereotactic frame; the use of fine glass needles fabricated from glass capillaries minimizes 
the extent of tissue damage. A small diameter Hamilton syringe can also be used in place of 
the glass needle; the Hamilton syringe can be mounted onto a micro-pump such as the WPI 
UltraMicroPump III, which is directly attached to a stereotactic frame.
The second approach utilizes a stereotactically implanted cannula guide not only to deliver 
virus but also to direct an optical fiber to the same brain area of interest (Fig. 3a). In this 
approach, the use of a single cannula guide for both viral vector delivery and optical fiber 
targeting ensures the co-registration of transduced brain area and light illumination. The use 
of cannula guides and infusion cannulae is a well-suited method for infusion of compounds 
into specific brain areas. Cannula systems consist of three major components: cannula guide, 
injection (or internal) cannula and dummy cannula. The projection length of each 
component can be customized for each component depending on the brain region of interest. 
Depending on the experimental application, the material composition and physical 
dimensions of each component can also be varied; e.g., silica instead of steel cannulae are 
more suitable for integration with magnetic resonance imaging, and larger diameter cannula 
guides can be used with bigger rodents such as rats to accommodate the insertion of a larger 
diameter optical fiber to increase the volume of illumination. The cannula guide is 
chronically implanted onto the skull of each experimental subject (Fig. 2h). A dummy 
cannula (stylet and screw cap) is temporarily inserted into the cannula guide between 
experiments to prevent clogging and infection. During behavioral experiments, an optical 
fiber can be inserted through the cannula guide to illuminate the light-sensitive neurons. In 
addition, bilateral cannula systems are suitable for targeting multiple brain regions within 
the same experimental subject.
Choice of light sources: there are several factors to be considered, including the intensity of 
light needed to reliably activate a sufficient volume of tissue and the ability to deliver high 
frequencies of light flashes to the experimental sample. For in vivo setups, it is also 
important to consider the mechanics and co-registration of the light delivery with the opsin-
expressing brain region. For in vitro experiments where the tissue sample is manipulated 
under a microscope, most conventional light sources such as halogen/xenon arc lamps, 
LEDs and lasers can be directly coupled to the microscope’s light path. Light flashes can be 
generated either by a lamp coupled to a fast shutter (e.g., Lambda DG-4 or Uniblitz shutter) 
or by directly modulating the intensity of light output using a waveform generator (lasers 
and LEDs; for optimal excitation wavelengths see Table 1).
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For in vivo light delivery in freely moving animals, high power lasers (~10–15 mW output at 
the tip of a 100 μm fiber) and LEDs are most suitable. For superficial stimulation of cortical 
layers, commercially available small LEDs can also be directly mounted above the brain 
over a thinned skull area or cranial glass window15,24. To target deep brain structures, we 
have found that thin optical fibers can be used to efficiently transmit sufficient powers of 
light to the target area8,49. Optical fibers are versatile elements that can be fused to recording 
electrodes (creating an optrode24 as described below for electrophysiological readout) and 
coupled to lasers and LEDs by FC/PC connectors. For mice, up to 300 μm fibers (bare fiber 
without plastic cladding) can be used without compromising animal movement, whereas we 
find that rats can tolerate up to 400 μm fibers. The length of the bare optical fiber can be 
customized based on the depth of the brain area by removing the precisely suitable length of 
plastic cladding. Mammalian brain tissue scatters light heavily, but ~10% of initial light 
power density remains at a distance from the fiber tip of ~500 μm8,49.
To avoid fiber breakage resulting from repeated insertion through the cannula guide system, 
a short fiber segment can be permanently implanted in the target region. During 
experiments, this short indwelling fiber segment can be coupled to a longer fiber connected 
to the laser by a custom fiber-to-fiber connector (Doric Lenses, Quebec, Canada). This 
strategy avoids fiber breakage, minimizes damage to brain tissue compared with implanted 
cannulas and reduces the likelihood of infection due to environmental exposure through the 
cannula. However, the fiber connector can lead to up to 50% loss of transmitted light, which 
may be overcome with more powerful laser diodes.
Choice of behavioral subjects: it is important to choose the appropriate species and genetic 
background according to the behavioral assay. For example, BALB/C animals are more 
suitable than C57BL6/J animals for anxiety and depression studies, whereas C57BL6/J are 
preferred over BALB/C for locomotor and cognitive studies51. When using transgenic 
mouse lines, it is often important to make sure that the mice are backcrossed (at least for six 
generations)52 to the appropriate genetic background.
Mechanical design considerations for behavioral equipments: during optogenetic behavioral 
experiments, each animal subject will have an optical fiber tethered to the skull throughout 
the experiment. Therefore, each subject should undergo sufficient habituation for the 
behavioral setup. Certain kinds of experimental apparatus containing obstacles such as 
doors, tunnels or closed compartments may need to be modified to allow free passage of the 
optical fiber. In some experiments, the acute insertion and removal of an optical fiber before 
and after the behavior test may be stressful for the experimental subject; therefore, previous 
handling will help alleviate this stress. A fiber commutator (Doric Lenses) may be used to 
relieve tension in the fiber and provide more rotational freedom for the experimental 
animals.
Summary—We have provided a compact collection of our key technical insights and 
protocols for optogenetic targeting of deep brain structures in mammals, as well as our 
protocols for major readout strategies, both in vivo and ex vivo. These methods promise to 
permit systematic exploration of brain circuits properties that would otherwise be intractable 
for this kind of work. Together these protocols are intended to facilitate the widespread and 
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versatile interrogation of circuit dynamics underlying mammalian behaviors in health and 
disease.
MATERIALS
REAGENTS
Virus production: lentiviral plasmids
• Channelrhodopsin vectors
– pLenti-CaMKIIa-hChR2(H134R)-EYFP-WPRE
– pLenti-Synapsin-hChR2(H134R)-EYFP-WPRE
– pLenti-CaMKIIa-VChR1-EYFP-WPRE
– pLenti-EF1a-hChR2(H134R)-EYFP-WPRE
– pLenti-CaMKIIa-hChR2(H134R)-mCherry-WPRE
• Halorhodopsin vectors
– pLenti-CaMKIIa-eNpHR-EYFP-WPRE
• SFO channelrhodopsin vectors
– pLenti-CaMKIIa-hChR2(C128A)-EYFP-WPRE
– pLenti-CaMKIIa-hChR2(C128S)-EYFP-WPRE
– pLenti-CaMKIIa-hChR2(C128T)-EYFP-WPRE
• Lentivirus support plasmids
– pCMVdeltaR8.74
– pVSVg ▲ CRITICAL These plasmids can be obtained from the Deisseroth 
laboratory directly (http://www.optogenetics.org) or from the Deisseroth 
plasmid list at Addgene. University-based virus production services, such as 
the virus vector cores at the University of North Carolina and University of 
Pennsylvania, will accept plasmid DNA and produce ready-for-injection 
virus for a fee.
Virus production: mammalian expression vector plasmids for transient 
transfection
• Channelrhodopsin vectors
– pcDNA3.1/VChR1-EYFP
– pcDNA3.1/hChR2(H134R)-EYFP
– pcDNA3.1/hChR2(H134R)-mCherry
• OptoXR Vectors
– pcDNA3.1/opto-α1AR-EYFP
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– pcDNA3.1/opto-β2AR-EYFP
Virus production: cre-dependent DIO AAV vectors
• pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-hGHpA
• pAAV-EF1a-double floxed-eNpHR-EYFP-WPRE-hGHpA ▲ CRITICAL These 
plasmids can be obtained directly from the Deisseroth laboratory (http://
www.optogenetics.org) or from the Deisseroth plasmid list at Ad-dgene. 
University-based virus production services, such as the virus vector cores at the 
University of North Carolina and University of Pennsylvania, will accept plasmid 
DNA and produce ready-for-injection virus for a fee.
• 293FT cells (Invitrogen, cat. no. R700-07)
• Dulbecco’s modified Eagle’s medium (DMEM) (Invitrogen, cat. no. 12-604Q)
• UltraCULTURE serum-free medium (Lonza, cat. no. 12-725F)
• Penicillin–streptomycin–L-glutamine mixture (Lonza, cat. no. 17-718R)
• Sodium pyruvate solution (Lonza, cat. no. 13-115E)
• Sodium bicarbonate solution (Lonza, cat. no. 17-613E)
• Phosphate buffered saline (PBS) without Ca2 + and Mg2 + (Lonza, cat. no. 17-516F)
• Defined fetal bovine serum (HyClone, cat. no. SH30070.03)
• Sodium butyrate (Sigma, cat. no. 19364-1G)
• HEPES (Sigma, cat. no. 54457-50G-F)
• Sodium phosphate dibasic (Sigma, cat. no. 71636-250G)
• Sodium chloride (Sigma, cat. no. 71376-1KG)
• Hexadimethrine bromide (Sigma, cat. no. 107689-10G)
• Sodium hydroxide (Sigma, cat. no. 71689-500G) ! CAUTION Strong base, handle 
and store according to hazardous material protocol.
• Distilled H2O (Lonza, cat. no. 17-724F)
• Calcium chloride 2 M stock solution (Quality Biological, cat. no. 351-130-061)
Stereotactic injection and cannula implantation
• Anesthetics (Mice: Ketamine 80 mg kg−1 and Xylazine 12 mg kg−1; Sigma, cat. no. 
K113; Rats: 80 mg kg−1 and Xylazine 6 mg kg−1, Sigma, cat. no. K4138). 
Alternatively, isoflurane may also be used. ! CAUTION Ketamine is a controlled 
substance and should be handled according to relevant rules of the host institutions. 
Isoflurane is a highly volatile substance and a proper fume hood and ventilation 
device should be used.
• Analgesics (Rats: Buprenorphine 0.01–0.05 mg kg−1; Mice: Buprenorphine 0.05–
0.1 mg kg−1 subcutaneous, Sigma, cat. no. B9275) ! CAUTION Buprenorphine is 
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a controlled substance and should be handled according to relevant rules of the host 
institutions.
• Lubricant eye ointment (Pharmaderm, cat. no. NDC 0462-0211-38)
• Sterile PBS (PBS 10×, Gibco, cat. no. 70011)
• Ethanol (Sigma, cat. no. 459836) ! CAUTION Ethanol is flammable. Avoid 
exposure to ignition.
• Hydrogen peroxide 30% (Sigma, cat. no. 31642)
• C&B metabond (Parkell, cat. no. IS380)
• Dental cement (Stoelting, cat. no. 51459)
• Tissue adhesive (Fisher, cat. no. NC9259532)
• Paraffin oil (Fisher, cat. no. BP26291)
• Betadine (PurduePharma, cat. no. a8658)
• 8-week old C57BL/6J mice (The Jackson Laboratory, cat. no. 000664)
! CAUTION All experiments using animals should be carried out under 
institutional and national guidelines.
VSD imaging
• D(+)-Sucrose (Fluka, cat. no. 8410026)
• D(+)-Glucose (Sigma, cat. no. S6297)
• NaCl (EMD Chemicals, cat. no. SX0420-1)
• KCl (Fluka, cat. no. 60128)
• NaH2PO4 (Fluka, cat. no. 74196)
• NaHCO3 (Sigma, cat. no. S6297)
• 2 M CaCl2 stock solution (Quality Biological, cat. no. 351-130-061)
• 2 M MgCl2 stock solution (Quality Biological, cat. no. 340-034-061)
• RH 155 (AnaSpec, cat. no. 84726)
• Agarose (Invitrogen, cat. no. 16500100)
• Super Glue (Duro, cat. no. SUP-1)
EQUIPMENT
Virus production
• 0.45 μm Low-protein binding filter flask (Millipore, cat. no. SCHVU02RE)
• T-75 and T-225 tissue culture flasks (Nunc, cat. nos. 156499 and 159934)
• Four-layer cell factory culture flask (Nunc, cat. no. 140004)
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• Ultracentrifuge tubes (Beckman Coulter, cat. no. 344058)
• Beckman Coulter Allegra X-12 bench-top centrifuge (Beckman Coulter)
• Beckman Coulter L-100 K preparative ultracentrifuge (Beckman Coulter)
• Beckman Coulter SW-28 ultracentrifuge rotor (Beckman Coulter)
Stereotactic injection and cannula implantation
• Surgical tools including scissors, forceps and scalpel blades (Fine Science Tools)
• Small animal stereotactic frame (Kopf Instruments, cat. no. 922 for mice, cat. no. 
955 for rat) with cannula holder (Kopf Instruments cat. no. 1766-AP)
• Programmable microsyringe pump (WPI, cat. no. SP220I)
• 10 μl Hamilton microsyringe (WPI, cat. no. nanofil) and tubing (Intramedic, cat. 
no. 4705)
• Cannula guide for 200 μm fiber in mice (PlasticsOne, cat. no. C313GS-5/SPC) 
internal/injector cannula (PlasticsOne, cat. no. C313IS-5/SPC) and dummy cannula 
(PlasticsOne, cat. no. C313DCS-5/SPC). The length of the cannula guide and 
internal cannula can be customized for desired target depth (recommended length 
for the cannula guide is 0.5 mm above the target region; internal cannula should 
have a projection length of 0.5 mm beyond the cannula guide tip; dummy cannula 
should be flush with the tip of the cannula guide).
• Dissection stereomicroscope (1–×10) with stand (Leica MZ6, cat. no. 10445614)
• Cotton swabs (Puritan Medical Products, cat. no. 25-806 10WC)
• High-speed micro drill with charger (Fine Science Tools, cat. no. 18000-17)
• 0.5 mm Micro drill stainless steel burrs (Fine Science Tools, cat. no. 19007-05)
• 0.9 mm Micro drill stainless steel burrs (Fine Science Tools, cat. no. 19007-05)
• 1 ml Syringes with subcutaneous needles (VWR, cat. no. 82002-326)
• Surgical suture (Myco Medical, cat. no. SK7772)
• Heating blanket (Fine Science Tools, cat. no. 21061 or 21060)
• Epoxy glue (Fisher, cat. no. NC9863515)
Optrode (integrated fiber-electrode) recording
• 473 nm diode laser (Cryst Laser, cat. no. BCL-473-050; 50mW, 473nm, TEMoo 
CW laser with TTL on/off, analog output intensity modulation, PC connector at 
laser output)
• Optical fiber (ThorLabs, cat. no. BFL37-200 for 200 μm fiber; cat. no. BFL37-300 
for 300 μm fiber; fibers need to have a FC end to connect to the PC adapter on the 
output of the laser; length can be specified depending on the experimental setup; 
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recommended to have at least 1 m of slack fiber from the head of the animal to the 
first fiber fixture).
• Fiber stripping tool (300 μm fiber: ThorLabs, cat. no. T18S31; 200 μm fiber: 
ThorLabs, cat. no. T12S25)
• Electrodes, tungsten, 1 mΩ, ~125 μm (AM systems, cat. no. 573220)
• Electrode holder (Kopf Instruments, cat. no. 1774)
• Amplifier (AM systems, model 1800 2-channel microelectrode AC amplifier, cat. 
no. 700,000)
• Data recording system (Axon Instruments/Molecular Devices Digidata 1440A or 
previous Digidata 1320 series, with pCLAMP 10 software)
In vivo optical stimulation for behavioral studies
• Arbitrary waveform generator, lasers and optical fiber (Agilent, cat. no. 33220A)
• Light power meter (ThorLabs, sensor, cat. no. S130A, and digital console, cat. no. 
PM100D)
• Dust cap (PlasticsOne, cat. no. 303DC/1)
• Custom-made aluminum rotating optical commutator (Doric Lenses)
• Thy1::ChR2–EYFP line 18 transgenic mice (The Jackson Laboratory, cat. no. 
007612) ! CAUTION all experiments using animals should be carried out under 
institutional and national guidelines.
VSD imaging
• Olympus BX51W upright microscope (Olympus)
• ×4 Objective (Olympus XL Fluoro ×4/340 objective, 0.28 NA, Olympus)
• Stable light source for VSD illumination (Olympus, cat. no. TH4-100)
• VSD imaging filter cube in Olympus filter housing (Chroma Technologies, 
emission filter, cat. no. D710/40; dichroic mirror, cat. no. 665DCXXR)
• Slice perfusion chamber (Siskiyou, cat. no. PC-V)
• High-speed CCD camera and processor with preconfigured Dell Optiplex 755 
(SciMedia, cat. no. MiCAM02)
• Ultra-fast optical filter switcher and light source for providing optical stimulation 
(Sutter Instruments, cat. no. Lambda DG-4)
• Excitation filters (Semrock, ChR2, cat. no. FF01-470/22-25, NpHR, cat. no. 
FF01-593/40-25)
• Cell strainers (BD Falcon, cat. no. 352360)
• Illumination filter for RH155 imaging (Chroma Technologies, cat. no. D710/40)
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• Slice anchor (Warner Instruments, cat. no. SHD-26H/2)
• Waveform generator (Agilent Technologies, cat. no. 3320A)
• 2-Channel peristaltic pump (Rainin, RP-1 pump, cat. no. 7103-052)
• Tygon Tubing 1/16″ I.D. 1/8″ O.D. and 1/32″ wall (US Plastics, cat. no. 57102)
• Connectors for tubing (Harvard Apparatus, cat. no. 721410)
• Coaxial cables
• Dissection tools (Fine Science Tools)
• Vacuum centrifuge for evaporation of solvents used in preparation of dye aliquots 
(Savant DNA Speed Vacuum)
• Vibrating slice cutter (Leica Microsystems, cat. no. VT 1000S)
• Table-top laboratory animal anesthesia system (VetEquip, cat. no. 901806)
• Blades (Fine Science Tools, cat. no. 10050-00)
• 95% Oxygen/5% CO2 (Praxair, cat. no. OXM)
• Shutter (Uniblitz, cat. no. Vmm-D1)
• Air table (Newport)
• Microscope-fixed stage (Sutter Instruments, cat. no. MT-1000/Y51)
• Crystallizing dishes for slice recovery (VWR, cat. no. 89000/290)
• 50 and 1,000 ml beakers (Corning, cat. nos. 1000-50 and 1000-1L)
• 1.5 ml Microcentrifuge tubes (Eppendorf, cat. no. 022364111)
• 10 cm Petri dish (BD, cat. no. 351005)
• Parafilm M (VWR, cat. no. 52858-000)
REAGENT SETUP
Virus injection setup—Fill the syringe, the tubing and the glass needle or injection 
cannula with paraffin oil. Load the virus solution in the needle or injection cannula using the 
programmable microsyringe pump.
D-10 cell maintenance medium—Prepare 500 ml of D-10 medium by supplementing 
500 ml of DMEM with 50 ml of fetal bovine serum, 5 ml of penicillin–streptomycin–L-
glutamine mixture, 5 ml of sodium pyruvate and 5 ml of sodium bicarbonate. The final 
mixture can be stored at 4 °C for 1 month.
Virus production medium—Prepare serum-free virus production medium by 
supplementing 500 ml of UltraCULTURE with 5 ml of penicillin–streptomycin–L-
glutamine mixture, 5 ml of sodium pyruvate and 5 ml of sodium bicarbonate. The final 
mixture can be stored at 4 °C for 1 month.
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20% Sucrose solution—Prepare 10 g of sucrose and then add PBS to a final volume of 
50 ml. Filter using 0.22 μm filter and then store at 4 °C for up to 1 month.
2 × HBS buffer—To 450 ml of distilled H2O, add 5.96 g of HEPES (50 mM), 0.106 g of 
Na2HPO4 (1.5 mM) and 8.18 g of NaCl (280 mM). The pH should initially be ~5.8. Titrate 
with NaOH to 7.05 (use 5 M NaOH first and then switch to 1 M NaOH). Bring the final 
volume to 500 ml and then filter with 0.22 μm filter. The solution is stable at room 
temperature (RT, 22 °C) for 6 months.
Cutting solution—In ddH2O add 120 mM sucrose, 64 mM NaCl, 2.5 mM KCl, 1.25 mM 
NaH2PO4, 25 mM NaHCO3 and 10 mM glucose. Store at 15 °C. Remains fresh for 2 weeks.
Artificial cerebral spinal fluid (ACSF), 10× stock solution—In ddH2O add 124 mM 
NaCl, 3 mM KCl, 1.25 mM NaH2PO4, 26 mM NaHCO3, 10 mM glucose, 2.4 mM CaCl2 
and 1.3 mM MgCl2. ▲ CRITICAL The solution must be freshly prepared.
Preparation of dye aliquots—Dilute 25 mg powder (MW: 950.3 g mol−1) in 5 ml 
ethanol and aliquot into ten 0.5 ml aliquots (5 mg ml−1) in 1.5 ml microcentrifuge tubes. 
Evaporate the solvent from aliquots by centrifuging it in a vacuum centrifuge until dry (~30 
min, drying rate: medium, no heat). Each aliquot will contain 2.5 mg of RH 155 dye. Dried 
aliquots may be stored at 0 °C for up to 1 year.
Preparation of slice staining solution—On the day of experiment, transfer 2.5 mg of 
RH 155 dye into 25 ml of ACSF to yield a final concentration of 0.1 mg ml−1. Minimize the 
exposure to light with aluminum foil wrapping and store at RT. Equilibrate the solution with 
95% CO2/5% O2.
Agarose blocks for slicing—Prepare 1% agarose solution by adding 1 g of agarose into 
100 ml of distilled water. Heat the agarose/water mixture in a microwave until agarose has 
completely dissolved (~1 min at high heat). Cool to 50 °C and then pour the agarose solution 
into 10 cm petri dishes (~50 ml per petri dish). After the agarose has solidified, wrap the 
plates with parafilm to avoid evaporation and store at 4 °C for up to 6 months. On the day of 
experiment, cut the block large enough to support brain samples (1 cm × 0.5 cm × 0.5 cm).
PROCEDURE
Production of recombinant lentivectors for optogenetic gene delivery in mammals
1| Cell preparation Aspirate the growth medium from one 95% confluent T-225 
flask of 293FT cells. Gently rock the flask to ensure complete coverage of the 
cell monolayer and incubate at room temperature for 5 min or until all of the 
cells have detached. Add 5 ml of D-10 to the flask to neutralize trypsin present 
in the medium and pipette three times to break up any cell clumps.
▲ CRITICAL STEP It is important to use low passage 293FT cells for the 
production of viruses. To make sure that the cells are always in the fastest 
growth phase, never let the cells approach full confluence.
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2| Split the 10 ml of cell suspension into four new T-225 flasks. Add 30 ml of fresh 
room temperature D-10 to each flask. Gently rock the flasks to ensure that the 
cells are evenly distributed in the flask. Put all four flasks into a 37 °C CO2 
incubator for 2 d or until 95% confluent.
3| Harvest the cells from each of four 95% confluent T-225 flasks of 293FT cells 
as described in Step 1. Transfer all the cells into 500 ml of room temperature 
D-10 medium, mix, and place the cell and medium mixture into one four-layer 
cell factory. Transfer the cell factory to a 37 °C CO2 incubator for 24 h.
4| Transfection of cell factory In a 50 ml conical tube, prepare the following 
mixture: 690 μg of lentivirus plasmid (e.g., pLECYT and pFCK-hChR2-
mCherry), 690 μg of pCMVdeltaR8.74, 460 μg of pVSVg and 5.7 ml of 2 M 
CaCl2 solution. Mix gently and bring the total volume to 23.75 ml with distilled 
H2O. Mix thoroughly.
5| Add 23.75 ml of 2× HBS to the DNA–CaCl2 mixture. Mix thoroughly and 
quickly. Then transfer directly into 500 ml of room temperature D-10.
▲ CRITICAL STEP Mix the DNA–CaCl2 with 2× HBS quickly and then 
transfer to room temperature D-10 immediately.
Short but thorough mixing ensures efficient formation of small calcium 
phosphate precipitates.
6| Remove the old medium from the four-layer cell factory and replace with the 
D-10 containing the calcium phosphate transfection mix. Transfer the plate back 
to the incubator for 15 h
7| Remove the transfection medium from the cell factory and gently wash using 
200 ml of fresh D-10. Add 400 ml of fresh room temperature D-10 to the cell 
factory. Put cells back into incubator for 8 h
! CAUTION The medium from the cell factory may contain recombinant viral 
vectors. Apply bleach to the medium to decontaminate.
8| At 24 h post transfection, remove medium from the cell factory and replace with 
200 ml of Virus Production Medium supplemented with 5 mM Na butyrate. 
Return the cell factory into the incubator.
▲ CRITICAL STEP Cells are easily detached at this stage and should be 
handled gently.
! CAUTION The medium from the cell factory may contain recombinant viral 
vectors. Apply bleach to the medium to decontaminate.
9| Virus harvest Treat six ultracentrifuge tubes by spraying with ethanol and air-
drying in the tissue culture hood.
10| At 48 h post transfection, collect the virus containing supernatant into four 50 ml 
conical tubes and centrifuge for 5 min at 500×g.
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11| Prewash a low-protein binding 0.45 μm filter flask with 30 ml of D10 medium, 
then filter the virus-containing supernatant
12| Divide the filtered virus-containing supernatant among the six centrifuge tubes
13| Pipette 2 ml of 20% sucrose solution to the bottom of the centrifuge tube.
▲ CRITICAL STEP It is important to pipette slowly so that the sucrose 
solution forms a discrete layer.
14| Centrifuge in a Beckman SW-28 rotor for 2 h at 82,700g at 4 °C.
15| Gently carry the centrifuge tubes back to the tissue culture hood and pour out the 
supernatant. There should be a tiny semi-transparent pellet at the bottom of each 
tube that resembles a soft contact lens. Dry the side of each tube with Kimwipe.
! CAUTION Supernatant may contain trace virus. Apply bleach to the medium 
to decontaminate.
16| Add 100 μl of cold PBS to the first tube and resuspend the pellet by swirling and 
gentle pipetting.
▲ CRITICAL STEP Excessive pipetting will degrade the virus.
17| Transfer the medium from the first centrifuge tube into the next tube to 
resuspend the second pellet. Repeat for the four additional tubes
18| Pipette the virus solution into an Eppendorf tube and spin the solution at 1,000g 
for 5 min to remove unsuspended virus debris. Centrifugation can be carried out 
at either room temperature or 4 °C.
19| Aliquot the supernatant and store at − 80 °C for up to 1 year.
▪ PAUSE POINT The supernatant can be stored at − 80 °C for up to 1 year.
Stereotactic injection and cannula placement into the rodent brain (Fig. 2)
20| Animal preparation. C57BL/6 mice (15–30 g) or Fisher rats (~200–300 g) 
should be housed and handled according to institutional and national guidelines.
21| Ensure that all surgical tools are clean and sterile. Disinfect the area with 70% 
ethanol and sterilize all tools by autoclaving or immersion in a disinfectant.
▲ CRITICAL STEP Perform all the surgeries under aseptic conditions.
22| Anesthetize rodents using 1.5% isoflurane (for surgeries longer than 1 h) or i.p. 
injection (90 mg kg−1 ketamine and 5 mg kg−1 xylazine for rats; 80 mg kg−1 
and 15–20 mg kg−1, respectively, for mice).
▲ CRITICAL STEP Check for the absence of toe-pinch reflex. Dispose of 
excess anesthesia according to institutional regulations.
? TROUBLESHOOTING
23| Apply ophthalmic ointment to prevent eye drying
24| Use a heating pad to maintain the body temperature at 35 °C
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25| Place the animal in a stereotactic frame. Fix the first ear (or head) bar and 
appose the animal’s ear canal to the ear bar by applying moderate pressure; 
place the second ear bar in the opposite ear while gently holding the animal; 
insert the mouth holder between the jaws of the animal; and finally, attach the 
nose holder to the animal using low pressure.
▲ CRITICAL STEP Correct head position in the stereotactic frame allows tilt, 
but no lateral movement of the head.
26| Shave and clean the head, wipe with 70% ethanol and betadine
27| Inject saline solution subcutaneously to prevent dehydration during surgery (30 
ml kg−1 of body weight: ~0.5 ml for adult mouse and ~5.0 ml for adult rat).
28| Make a midline scalp incision of ~1 cm using scalpel. Gently pull the skin aside 
to expose the skull (Fig. 2a). Clean the skull with cotton swabs immersed in 
hydrogen peroxide.
▲ CRITICAL STEP The thin membranes covering the skull will be disrupted 
immediately upon exposure to hydrogen peroxide and will appear as a layer of 
white foam. Stop the reaction with PBS immediately after the application of 
hydrogen peroxide by wiping with a cotton swab soaked in PBS and remove 
debris with a scalpel blade.
29| After cleaning the skull with cotton swabs, identify the bregma (the point of 
intersection of the sagittal suture with the curve of best fit along the coronal 
suture) and the lambda (midpoint of the curve of best fit along the lambdoid 
suture)53 (Fig. 2b).
▲ CRITICAL STEP Align the bregma and the lambda to the same dorsal–
ventral (or z) coordinates by adjusting the height of the nose clamp on the 
stereotactic frame until the head is flat. Align the x and y tilt of the animal’s 
head by measuring the x and y coordinates of the bregma and the lambda.
30| Use a brain atlas to identify the coordinates for the target structure
31| Move to the targeted area defined by the coordinates (Fig. 2c). Slowly make a 
small craniotomy (slightly larger diameter than the cannula guide) using a drill 
mounted on the stereotactic frame (Fig. 2d).
▲ CRITICAL STEP To minimize damage to the brain, do not drill through the 
dura and instead use fine forceps to remove the dura. This is crucial for cortical 
injections.
? TROUBLESHOOTING
32| Thaw the virus on ice. Lentivirus can be kept on ice for 6 h without significantly 
affecting the titer, whereas AAV can be stored at temperatures as warm as 4 °C 
for at least 1 month without the loss of significant titer
33| Place the cannula in the cannula holder on stereotactic frame and slowly lower 
the cannula guide into the brain.
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? TROUBLESHOOTING
34| Dry the skull with cotton swabs. Apply a thin layer of C&B Metabond where the 
dental cement will be in contact with the skull, including around the cannula 
pedestal
35| Once the C&B Metabond hardens, release the cannula from the holder and 
withdraw the cannula holder without moving the cannula guide (Fig. 2e). Secure 
the cannula pedestal with dental cement and ensure that at least two rounds of 
threads in the cannula pedestal are exposed (Fig. 2f).
36| Glue the skin back with Vetbond surgical adhesive (Fig. 2g).
37| Perform virus injection during surgery (A) or after surgery (B). It may be 
necessary to titrate the virus (Box 1).
BOX 1
CRITICAL STEP VIRUS INJECTION AND VALIDATION
1. It is important to quantitatively validate the targeting of virus 
injection.
2. It is recommended to perform several injections with increasing 
volumes of virus at the same concentration.
3. Start at 0.2 μl per injection site with 0.2 μl increments up to 1 μl final 
injection volume.
4. Assess spatial extent, efficacy and specificity of transduction by 
histological analysis.
A. Virus injection during surgery (We describe here our protocol using the 
micropump from WPI and with special attention on the surgical 
procedure and cannula implantation for virus injection into rodent brain. 
Virus can also be delivered using glass capillaries to minimize tissue 
damage54.)
i. Inject 0.2–0.5 μl of virus into the brain using a 10 μl microsyringe 
and a thin 34 G metal needle.
ii. Control the injection volume and flow rate (0.1 μl min−1) with a 
high precision injection pump (Fig. 2h).
iii. After injection leave the needle in place for 10 additional min to 
allow the virus to diffuse in the brain. Withdraw the needle slowly 
afterwards.
iv. After completely withdrawing the needle check that it is not 
clogged by pumping out a small droplet (0.1 μl).
B. Virus injection after surgery
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i. Carry out this procedure after the dental cement is dry, while the 
animal is still anesthetized.
ii. Use an internal cannula fitted to the cannula guide’s length (Fig. 
2i).
iii. Connect the internal/injector cannula to the tubing filled with oil 
(which is connected to the microsyringe), load it with virus 
solution and place it into the cannula guide.
iv. Infuse the virus at a very low rate (0.1 μl min−1) as described 
above.
? TROUBLESHOOTING
38| Give buprenorphine (0.03 mg kg−1) subcutaneously following the surgical 
procedure to minimize pain/discomfort.
39| Let the animal fully recover in a clean cage placed over a heating blanket (Fig. 
2i). Monitor the recovery of the animal every 10 min.
40| Simultaneous optical stimulation and electrical recording in living mice 
with the optrode method
Prepare the optrode by firmly attaching an extracellular tungsten electrode (1 
mΩ, ~125 μm) to an optical fiber (~200 μm) (TIMING 10 min).
▲ CRITICAL STEP The tip of the electrode must be deeper (>0.3mm) than the 
tip of the fiber to ensure illumination of the recorded neurons and prevent 
artifacts24.
▲ CRITICAL STEP Do not contact the tip of the electrode.
41| Prepare animals by performing craniotomies (A) or use animals that have a 
cannula implanted in the desired region (B).
! CAUTION All experiments using animals should be carried out under 
institutional and national guidelines.
A. New craniotomy above target region
i. Prepare the animal as described in Steps 20–31, in a stereotactic 
frame on an optics table. ▲ CRITICAL STEP Use a Faraday cage 
to shield out electrical noise.
B. Existing cannula above target region
i. Anesthetize the animal as described in Steps 22–24.
ii. Place animal in stereotactic frame (Step 25) so that the cannula is 
vertically aligned.
42| Use an electrode holder to mount the optrode (or optrodes for more than one 
location) on the stereotactic frame.
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43| Lower the optrode to the desired depth through the freshly made craniotomies or 
through the cannula.
▲ CRITICAL STEP Take all precautions not to damage the electrode tip. 
Avoid touching the skull or the cannula directly with the electrode tip; once the 
tip is safely inside the cannula it will not get damaged as it is lowered further.
44| Attach a ground wire to the scalp as a reference signal.
45| Connect the optical fiber to a laser diode of desired wavelength and the 
electrode to an amplifier. For single unit recordings the recorded signal is band 
pass filtered between 300 Hz and 5 kHz. For field potentials, low-pass filter the 
signal at 300 Hz.
46| Use an ADC board (e.g., Digidata) and control software (e.g., pClamp) to collect 
data and generate light pulses through the fiber.
? TROUBLESHOOTING
47| If desired, sacrifice the animal immediately after recording. The brain may be 
extracted and sectioned to verify opsin gene expression and accurate placement 
of the optrode or acute slices can be prepared for electrophysiology or VSDI.
Setting up optical stimulation for behavioral assays
48| Preparation of ONI fibers (Fig. 3). Prepare the ONI fiber using cannula parts 
from PlasticsOne. These consist of a screwing cap for securing the fiber to the 
animal’s head, a fiber guard from the internal cannula adapter and a bare fiber 
with length customized based on the depth of the target region. Prepare the 
screwing cap by drilling a ~2 mm diameter hole centrally on the top of a dust 
cap to allow the optical fiber to pass through (Fig. 3c,d).
49| Remove the metal tubing from the plastic pedestal of an internal cannula (Fig. 
3e,f).
50| Use a fiber stripping tool to remove ~40 mm of plastic coating from the bare end 
of an optical fiber (Fig. 3g).
51| Thread the fiber through the cap with the cap opening facing away from the FC 
connector on the fiber (Fig. 3h). Thread the fiber through the plastic pedestal so 
that the snap-on part faces away from the FC connector on the fiber (Fig. 3i).
52| Apply a very thin layer of glue to the interface of coated/uncoated fiber and slide 
the plastic pedestal onto the fiber so it is tight against the plastic coating on the 
fiber (Fig. 3j–l). Allow the glue to dry for 10 min.
▲ CRITICAL STEP Do not apply excess glue. Too much glue will set slowly, 
prevent the cap from fitting over the internal cannula and also prevent the 
internal cannula from snapping onto the cannula guide.
53| Insert the ONI fiber through a cannula guide (same dimensions as the ones 
implanted on the experimental animals) and ensure that the components snap 
tightly (Fig. 3m,n). Use a diamond knife to cut the fiber so that it projects 0.5 
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mm from the tip of the cannula guide (Fig. 3o,p). It is not necessary to polish the 
fiber end.
▲ CRITICAL STEP It is important to use a diamond knife so the fiber tip is 
flat to ensure consistent illumination. After cutting, check the fiber tip under a 
stereomicroscope.
54| Connect the FC end of the fiber to the PC connector on the output port of the 
laser. Connect the laser control box to a waveform generator.
55| Program the waveform generator with the desired stimulation protocol (i.e., 
pulse frequency, duration and intensity).
▲ CRITICAL STEP Use a power meter to measure the light output at the end 
of the fiber before and after behavioral testing.
56| In vivo stimulation for behavior. Insert the ONI fiber through the cannula 
guide on the animal’s head and tighten the screw cap to secure the fiber.
▲ CRITICAL STEP Extra care should be taken during fiber insertion to 
prevent breakage.
▲ CRITICAL STEP For most behaviors, it is necessary to habituate the 
animals to the experimental setup by practicing fiber insertion/removal several 
times. The animals should be placed in the behavioral testing room for at least 3 
h before behavioral testing.
? TROUBLESHOOTING
57| Begin behavioral testing. Stimulation can be applied by triggering the waveform 
generator.
58| Verify the cannula placement and opsin gene expression by post-behavioral 
histological analysis.
All-optical stimulation and activity imaging in slices using VSD
59| Optics setup On an upright microscope, set up the stimulation light source (e.g., 
DG-4) to interfere with the epifluorescence port. The light source or a shutter 
needs to be in place to allow precisely timed flashes of stimulation light.
60| Set up the VSD filters by placing the imaging filter cube carrying both the 
dichroic (reflect < 665 nm light to the tissue sample) and emission filter (710 nm 
bandpass).
61| Connect the halogen lamp to the diascopic lamphouse port and use this light 
source for illumination of RH 155-stained slices. Place the illumination filter 
(710 nm) into a slot in the condenser. This filter isolates 710 nm light from the 
diascopic lamphouse for illumination of RH 155-stained slices. RH 155 is an 
absorbance dye; the filter placed in the condenser filters the light coming from 
the bright field light source below the tissue sample, and the amount of 
transmittance reflects the changes in membrane voltage.
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62| Staining in RH 155 dye Prepare acute brain sections from the brain region of 
interest55. While the slices are recovering in cutting solution with perfusion of 
CO2/O2, prepare fresh ACSF solution.
▲ CRITICAL STEP Make sure that the pH of the ACSF is between 7.3 and 
7.4. Perfuse the ACSF with 95% CO2/5% O2 for 10 min before using.
63| Dilute one aliquot of RH 155 dye with 25 ml ACSF to prepare staining solution. 
The solution should appear dark blue in color.
▲ CRITICAL STEP It is important to minimize light exposure to the dye. 
Wrap aluminum foil around all dye containers and keep all the dye solutions in 
the dark.
64| Equilibrate the staining solution in 95%O2/5%CO2 at room temperature (25 °C) 
for 10 min.
▲ CRITICAL STEP Wrap foil around staining container and keep in dark.
65| Quickly transfer the slices from the water bath to the staining solution and 
incubate the slices in the dark for three hours while bubbling with 
95%O2/5%CO2.
▲ CRITICAL STEP Place slices flat and spaced evenly, completely immersed 
in solution. Minimize light exposure by wrapping containers in foil and staining 
in darkness. Consistent timing, dye concentration and staining area are crucial.
66| Setting up the sample and optimizing the image Transfer the slices in the cell 
strainer from the staining solution to fresh, ACSF equilibrated with 95% O2/5% 
CO2 to wash away excess dye. Incubate the slices in the fresh ACSF for 15 min. 
While the slices are recovering, perfuse the slice chamber on the microscope 
with equilibrated ACSF. The slices should be evenly stained dark blue.
67| Transfer a single stained slice from the cell strainer into the slice chamber on the 
microscope stage. Continue to perfuse the chamber with 95% O2/5% CO2 
ACSF.
68| Ensure slice stability by placing a slice anchor around the edges of the slice. 
Ensure Lycra strings from the slice anchor do not cover the region of interest.
69| Adjust the slice to place it in the center of the field of the view and adjust 
intensity of excitation light (from halogen light source) to enhance contrast 
while minimizing camera saturation.
▲ CRITICAL STEP Ensure 100% of the illumination light is directed to the 
camera. After positioning the slice, close the shutter for the halogen light source 
to minimize photobleaching. All imaging sessions should be carried out in the 
dark to minimize noise and photobleaching.
70| Stimulation and image acquisition Bear in mind that perfusion of ACSF 
during image acquisition can introduce motion artifacts. The camera can be set 
to trigger the function generator and DG-4, if desired. It is also recommended to 
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simultaneously record light-evoked field potentials and to validate the 
effectiveness of optical stimulation, slice health and proper configuration of the 
VSDI setup. Process images using MATLAB.
● TIMING
Steps 1–3, Preparation of cells for transfection: 2 d
Steps 4–8, Transfection and culturing of cells to produce lentivirus: 39 h
Steps 9–19, Harvesting, concentration and aliquoting of lentivirus: 4 h
Steps 20–39, Stereotactic injection of virus in rodents: 1–2 h. At least 2 weeks are 
required after injection before sufficient levels of opsin gene products are expressed in 
the brain.
Steps 40–47, Simultaneous optical stimulation and electrical recording in vivo: 2–3 h
Steps 48–58, Behavioral testing with in vivo optical stimulation: 2 or more hours 
depending on the specific behavioral experiment
Steps 59–61, Setting up optics for VSD imaging: 1 h
Steps 62–65, Staining brain sections with VSD: 3 h
Steps 66–69, Setting up samples for imaging and optimizing the settings: 30 min
Step 70, Acquiring VSDI images: 30 min
? TROUBLESHOOTING
Troubleshooting advice can be found in Table 3.
ANTICIPATED RESULTS
Virus-mediated cell-specific expression of microbial opsin genes in neural tissues
Both lentiviral and AAV vectors carrying an appropriate cell-specific promoter and the 
opsin gene of interest can mediate robust expression in targeted cell types (Fig. 4a–d)49. 
Injection of 1 μl of high titer VSVg pseudotyped lentivirus (>109 pfu ml−1) or AAV (>1012 
gc ml−1) into the cortex or the hippocampus can result in transduction volumes >1 mm3. 
Prolonged expression of any membrane protein driven by strong ubiquitous promoters, such 
as CAG, can lead to toxicity in neurons. However, when the transgene is driven by a reliable 
and strong cell-specific promoter, expression can be very well-tolerated, stable and also 
specific, with < 10% of transduced cells belonging to non-targeted cell types as identified by 
immunostaining for the marker protein. Thus far, both the human Synapsin I and murine 
CaMKIIa promoters have been used in viral systems (lentivirus or AAV) to drive strong 
pan-neuronal or excitatory neuron-specific expression, respectively, in the mammalian brain 
in vivo. The glial fibrillary acidic protein (GFAP) promoter can also be used to drive 
astrocyte-specific expression from a lentiviral vector. Other promising cell-specific 
promoters include ppHcrt8, Sst56 and CCK57 (see Table 2 for a list of previously reported 
cell-specific promoters). When using cell-specific Cre transgenic mice, 1 μl of doubly floxed 
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inverted opsin (DIO) Cre-dependent AAV can be delivered to the target brain area to 
achieve virtually 100% cell-specific expression in the Cre-expressing cell population.
With both lentivirus and AAV, microbial opsin genes will express stably for at least 6 
months after injection, and when tagged with a fluorescent protein marker, the transduced 
cells will exhibit strong membrane-localized fluorescence. Comparatively, ChR2 is better 
localized to the membrane than NpHR and VChR1, but it may still be difficult to identify 
the somata of ChR2–EYFP expressing cells in intact tissue. To improve the visualization 
and identification of expressing cells, the optogenetic protein and the fluorescent protein tag 
can be expressed as two separated proteins using IRES58 or 2A59,60 bicistronic linkers. 
Expressing different rhodopsins as separate proteins also ensures that both will integrate into 
the plasma membrane in the correct orientation. For most reliable optical control of axon 
terminals (Fig. 4e), it is important to achieve a high level of expression in the axonal 
membranes; therefore, although physiological effects can be seen earlier, for viral mediated 
expression, it is optimal to wait until 4 or more weeks after injection before conducting 
experiments.
Electrophysiological validation of functional expression
Depending on targeted cell type, the maximal evoked firing frequency will vary (for 
pyramidal neurons in the neocotex, cells expressing ChR2 can be driven to fire spikes up to 
30 Hz reliably, whereas other cell types such as fast-spiking interneurons will be able to fire 
at 100 Hz or more). Spiking properties in targeted cells depend on spike and illumination 
history as well as on membrane expression level and local illumination intensity; for any 
given cell type and circuit, a detailed characterization should be carried out to determine the 
efficacy of light evoked spike trains. To track and validate activity modulation, optrode 
recordings can be carried out in vivo (Fig. 4e). Artifacts, although much smaller than for 
electrical stimulation, can be occasionally observed61; when present, such artifacts are 
correlated with the onset and offset of the light pulse; amplitude depends on light power and 
can be reduced with proper grounding and use of electrodes with coating extending to the tip 
and staggered relative to the optical fiber by 300–500 μm, as is typically important in any 
case for proper illumination of the recorded area.
Imaging optogenetically controlled signals using VSD
Voltage-sensitive dyes imaging of optically evoked activity in neural circuits expressing 
light-gated ion channels allows for fast, all-optical interrogation and quantification of the 
spatiotemporal dynamics of ex vivo circuits. In general, brain sections prepared from 
younger animals (< 6 weeks) yield optimal signals; however, older animals may still be used 
but with reduced signal properties. Brain sections should be prepared with sufficient 
thickness to preserve network connections in the target circuit (e.g., ~300 μm for mice and 
~400 μm for rats). Because of the inherently low signal of VSDI (~0.1% change in 
absorbance or fluorescence) and high levels of optical noise, averaging individual pixels 
over multiple trials is often necessary. Along with averaging these pixels over time, several 
pixels can also be averaged over space (with reference to anatomical landmarks) to increase 
the signal-to-noise ratio. Software provided by Scimedia or other fast camera producers (i.e., 
Redshirtimaging) can carry out these initial tasks. However, more advanced post-processing 
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and quantitative analysis methods are often carried out in our laboratory using algorithms 
written in Matlab47, available upon request.
Optical stimulation of brain sections from a Thy1::ChR2–YFP transgenic mouse with blue 
(470 nm) light reveals quantitatively reproducible optical changes in the brain tissue (Fig. 
4f). The signal is typically strongest in the CA1 region, where ChR2 expression is highest. 
Signals are also seen in the entorhinal cortex, the subiculum and the dentate gyrus as a result 
of both direct activation of ChR2 and percolating circuit activity.
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Figure 1. 
Optogenetic tools. (a) Naturally occurring light-responsive effectors and their microbial 
sources: ChR2 from Chlamydomonas reinhardtii, VChR1 from Volvox carteri and NpHR 
from Natronomonas pharaonis; useful light wavelengths for each are indicated. ChR2 and 
VChR1 are cation-conducting channels and NpHR is a chloride pump. (b) Engineered 
synthetic rhodopsins for optical control of well-defined intracellular biochemical signaling. 
The intracellular loops of bovine rhodopsin have been replaced with the intracellular loops 
of G protein-coupled receptors (GPCRs) to yield light-activated chimeric GPCRs. Green 
light illumination leads to activation of the downstream Gq and Gs signaling pathways. (c) 
Action spectra. The absorbance wavelength of the voltage-sensitive dye (VSD) RH 155 is 
sufficiently separated from the light-sensitive range of all rhodopsins, therefore making it 
possible to integrate VSD imaging with optogenetic modulation. (d) Viral vectors for 
introducing microbial opsin genes into the brain. Top and middle: Lentiviral and AAV 
vectors can be used to deliver a cell-specific promoter along with the opsin gene and its 
fluorescent marker. Bottom: Cre-dependent adeno-associated virus (AAV) vector carries a 
doubly floxed inverted opsin (DIO) fusion gene. Upon transduction into Cre recombinase-
expressing cells, the opsin fusion gene will be irreversibly inverted and enable cell-specific 
gene expression. Part a was modified with permission from Nature4 (Nature © 2007; 
Macmillan Publishers Ltd.).
Zhang et al. Page 29
Nat Protoc. Author manuscript; available in PMC 2015 July 15.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 2. 
Stereotactic implantation of the cannula guide. (a) After mounting the animal into the 
stereotactic frame, a first incision is made to open the skin above the skull. The skin is 
gently pulled to the side to reveal the cranial sutures. (b) After quickly wiping the skull with 
hydrogen peroxide, the bregma and the lambda can be easily identified (marked spots). (c) A 
thin needle is used to align the skull. (d) A dental drill is used to create a small craniotomy 
at the desired location on the skull, without puncturing the dura. The dura is later removed 
using fine forceps to minimize damage to the cortex. (e) A cannula guide is implanted on the 
skull through the craniotomy. (f) Metabond and dental cement are used to secure the cannula 
guide to the skull. (g) Vetbond and sutures are used to close the incision around the 
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cannulation site. (h) An internal cannula guide connected to a pump is inserted through the 
cannula guide and is used to infuse virus into the target area in the brain. (i) The animal is 
allowed to rest in a recovery cage after surgical implantation. The surgery was conducted 
according to established animal care guidelines and protocols at Stanford University.
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Figure 3. 
Preparation of the optical fiber for in vivo neural control in mammals. (a) Diagram of the 
optical neural interface (ONI), consisting of a stereotactically implanted cannula, an optical 
fiber, and a solid state laser controlled by a signal generator. The fiber is prepared with the 
appropriate length to illuminate the target brain region. (b) The tools and parts (fiber with 
FC connection, dummy cannula, internal cannula, cannula guide, dental drill, super glue, 
diamond scribe and fiber stripping tool) needed to manufacture ONI fibers. (c,d) A drill is 
used to produce a small bore on the center of a cannula cap. (e,f) The steel tubing is 
removed from an internal cannula. The plastic adapter is used as the fiber guide. (g) A fiber 
stripping tool is used to remove the plastic cladding from a fiber to reveal the fiber core. (h) 
The bare fiber core is threaded through the bore on the cannula cap. (i,j) The plastic adapter 
from the internal cannula is also placed on the fiber. (k,l) Superglue is applied to the fiber to 
secure the plastic adapter against the plastic cladding on the fiber. The plastic adapter is held 
tightly against the fiber cladding for several minutes to allow the superglue to harden. (m) 
After superglue has hardened, the fiber is inserted through a cannula guide with the right 
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projection length for the target brain region. (n) The cannula guide is securely clipped into 
the plastic adapter. (o) A diamond scribe is used to remove the excess fiber from the tip of 
the cannula guide. (p) The finished ONI fiber is allowed to protrude from the tip of the 
cannula guide by ~0.5 mm. Part a was modified with permission7 (Nature © 2007; 
Macmillan Publishers Ltd.).
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Figure 4. 
Functional expression of microbial opsin genes in the rodent brain. (a) Fluorescence image 
superimposed on bright field image of the motor cortex of a wild-type mouse injected with 2 
μl lentivirus carrying the CaMKIIα::ChR2–EYFP construct, into layer V of the anterior M1 
cortical area (AP 2 mm; ML 2 mm; DV 2 mm); 2 weeks were allowed for expression before 
preparing 200 μm slices that were examined under confocal (images are z-projection of 
single planes). (b) The injection produced strong expression in layer V of the cortex (the 
dendrites projecting from layer V neurons to the surface of the brain are clearly visible). (c) 
Fibers from layer V of the cortex travel through the corpus callosum (CC) and striatum. (d) 
Axons terminating in target structures. (e) Optrode recording during optical stimulation of 
the subthalamic nucleus of a Thy-1::ChR2–EYFP mouse. Example trace shows ten pulses of 
5 ms blue light (470 nm) flashes delivered at 20 Hz. At right, zoomed view shows a single 5 
ms light flash and resulting evoked spike. (f) Fast all-optical interrogation: typical voltage 
sensitive dye imaging signal from an acute horizontal hippocampal slice stained with RH 
155. Trace shows the voltage changes in the slice resulting from 10 pulses of 10 ms blue 
light flashes delivered at 20 Hz. Acquisition rate: 200 Hz. The trace is averaged over four 
acquisition periods and a region of interest of 147 μm × 133 μm was defined in the 
entorhinal cortex. (Scale bars: a, 1 mm; b, 500 μm; c, 50 μm; d, 25 μm.)
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TABLE 3
Troubleshooting table.
Step Problem Possible reason Solution
22 Incomplete anesthesia: 
persistent response to toe 
pinch
High tolerance or clearance Administer additional 10% volume ketamine/xylazine (or 
corresponding isoflurane increment)
31 Poor cannula positioning 
observed during 
histological validation
Excess bleeding after 
craniotomy
Stereotactic coordinates based on 
brain atlas are not accurate for the 
experimental animal age or strain
Vessel trauma
Tune the co-ordinates for age and species
Place cotton swab over craniotomy site. When hemostasis is 
achieved, irrigate craniotomy site with sterile saline
33 Excess bleeding after 
cannula placement
Vessel trauma Place cotton swab over craniotomy site. When hemostasis is 
achieved, irrigate the site with sterile saline
37 No solution can be injected Needles may clog after 
advancement through intact tissue
Replace the needle
46 No electrical signal is 
recorded
Electrical noise observed 
during recording
Optical stimulation does 
not modulate physiology
Sensitive electrode tip has been 
damaged by contact
Ground loop present in the setup
Opsin-expressing cells may be 
distant from recording electrode
After confirming integrity of electrical connections, replace 
electrode
Check all converging grounds to the table and the table ground to 
the amplifier. Confirm that the ground wire is in contact with the 
tissue and provide ~30–50 μl saline to the ground wire to ensure 
electrical connectivity
Calculate relevant scattering parameters (accounting for light 
wavelength, intensity and source geometry) in the context of local 
neuroanatomy. Optrode may need to be redesigned accordingly or 
optrode positioning may need to be revised by complete retraction 
and replacement
56 Fiber breakage during 
behavior
Rotational behavior results in fiber 
torsion
Employ fiberoptic commutator to relieve torsion; some light loss 
may result
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